–Jin Yang-gon, CEO of HLB. Source = Newsis
–
[이코노믹리뷰=황진중 기자] HLB (028300) is scheduled to disclose its position on the 16th in relation to the report on the suspicion of false disclosure of FDA clinical results.
On the website, HLB said, “After receiving a request from the financial authorities, we express our deep regret that the fact that has not been confirmed as a situation that has not been confirmed is prematurely reported, causing confusion between the market and investors. I will hold you accountable.”
HLB added, “We will convey our position on this issue in detail through our YouTube channel at 2 pm today.” He added, “I am very sorry for causing concern to shareholders.”
– .
Related posts:
"Digital transformation is sometimes a big challenge"
Jean-Christophe Parent, director of Walibi Belgium: "This year, we will lose half of our turnover"
Fire brigades practice emergencies in a gas company in Wanzleben
US inflation expectations one year ahead fall to the same level as April 2021 - New York Fed survey
